Immune checkpoint inhibitors (ICI) in clear cell renal cell carcinoma (ccRCC) following high-dose interleukin-2 (IL-2).

Roy Elias,Isaac Alexander Bowman,Hans J. Hammers,James Brugarolas

Immune checkpoint inhibitors (ICI) in clear cell renal cell carcinoma (ccRCC) following high-dose interleukin-2 (IL-2).

2020

Roy Elias
Isaac Alexander Bowman
Hans J. Hammers
James Brugarolas

635Background: IL-2 can be curative in a small subset of ccRCC patients (pts). Recent data suggest that ICIs may lead to long lasting responses, and ICI therapy following progression on IL-2 seems ...

Keywords:

Cancer research
Pathology
Interleukin 2
Immune checkpoint
Clear cell renal cell carcinoma
Medicine
immune checkpoint inhibitors
long lasting

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations